Preparation and in vitro characterization of SN-38-loaded, self-forming polymeric depots as an injectable drug delivery system

Journal of Pharmaceutical Sciences

Volumn 101, Issue 10, 2012, Pages 3708-3717

  Manaspon, Chawan ^a   Hongeng, Suradej ^b   Boongird, Atthaporn ^b   Nasongkla, Norased ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Biodegradable polymers; Cancer; Controlled release; Depot; Site specific delivery; SN 38

Indexed keywords

FIRTECAN; MACROGOL; PHOSPHATE BUFFERED SALINE; POLYCAPROLACTONE; POLYLACTIDE; POLYMER;

ARTICLE; CANCER CELL; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG STABILITY; ENCAPSULATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; POLYMERIZATION;

EID: 84865349900     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23238     Document Type: Article

References (36)

1. Avgeropoulos NG, Batchelor TT. 1999. New treatment strategies for malignant gliomas. Oncologist 4(3):209-224.
2. Mrugala MM, Kesari S, Ramakrishna N, Wen PY. 2004. Therapy for recurrent malignant glioma in adults. Expert Rev Anticancer Ther 4(5):759-782.
3. Burke TG, Mi Z. 1993. Ethyl substitution at the 7 position extends the half-life of 10-hydroxycamptothecin in the presence of human serum albumin. J Med Chem 36(17):2580-2582.
4. Kolhatkar RB, Swaan P, Ghandehari H. 2008. Potential oral delivery of 7-ethyl-10-hydroxy-camptothecin (SN-38) using poly (amidoamine) dendrimers. Pharm Res 25(7):1723-1729.
5. Zhang JA, Xuan T, Parmar M, Ma L, Ugwu S, Ali S, Ahmad I. 2004. Development and characterization of a novel liposome-based formulation of SN-38. Int J Pharm 270(1-2):93-107.
6. Marier JF, Pheng L, Trinh MM, Burris 3rd HA, Jones S, Anderson K, Warner S, Porubek D. 2011. Pharmacokinetics of SN2310, an injectable emulsion that incorporates a new derivative of SN-38 in patients with advanced solid tumors. J Pharm Sci 100(10):4536-4545.
7. Yang X, Hu Z, Chan SY, Goh BC, Duan W, Chan E, Zhou S. 2005. Simultaneous determination of the lactone and carboxylate forms of irinotecan (CPT-11) and its active metabolite SN-38 by high-performance liquid chromatography: Application to plasma pharmacokinetic studies in the rat. J Chromatogr B Analyt Technol Biomed Life Sci 821(2):221-228.
8. Krauze MT, Noble CO, Kawaguchi T, Drummond D, Kirpotin DB, Yamashita Y, Kullberg E, Forsayeth J, Park JW, Bankiewicz KS. 2007. Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts. Neuro Oncol 9(4):393-403.
9. Ebrahimnejad P, Dinarvand R, Sajadi A, Jaafari MR, Nomani AR, Azizi E, Rad-Malekshahi M, Atyabi F. 2010. Preparation and in vitro evaluation of actively targetable nanoparticles for SN-38 delivery against HT-29 cell lines. Nanomedicine 6(3):478-485.
10. Kuroda J, Kuratsu J, Yasunaga M, Koga Y, Saito Y, Matsumura Y. 2009. Potent antitumor effect of SN-38-incorporating polymeric micelle, NK012, against malignant glioma. Int J Cancer 124(11):2505-2511.
11. Duan K, Zhang X, Tang X, Yu J, Liu S, Wang D, Li Y, Huang J. 2010. Fabrication of cationic nanomicelle from chitosan-graft-polycaprolactone as the carrier of 7-ethyl-10-hydroxy-camptothecin. Colloids Surf B Biointerfaces 76(2):475-482.
12. Matsumura Y. 2011. Preclinical and clinical studies of NK012, an SN-38-incorporating polymeric micelles, which is designed based on EPR effect. Adv Drug Deliv Rev 63(3):184-192.
13. Brem H, Langer R. 1996. Polymer-based drug delivery to the brain. Sci Med 3(4):52-61.
14. Storm PB, Renard VM, Moriarity JL, Tyler B, Wilentz RE, Brem H, Weingart JD. 2004. Systemic BCNU enhances the efficacy of local delivery of a topoisomerase I inhibitor against malignant glioma. Cancer Chemother Pharmacol 54(4):361-367.
15. Gabathuler R. 2009. Blood-brain barrier transport of drugs for the treatment of brain diseases. CNS Neurol Disord Drug Targets 8(3):195-204.
16. Wang PP, Frazier J, Brem H. 2002. Local drug delivery to the brain. Adv Drug Deliv Rev 54(7):987-1013.
17. Hatefi A, Amsden B. 2002. Biodegradable injectable in situ forming drug delivery systems. J Control Release 80(1-3):9-28.
18. Hatefi A, Knight D, Amsden B. 2004. A biodegradable injectable thermoplastic for localized camptothecin delivery. J Pharm Sci 93(5):1195-1204.
19. Khamlao W, Hongeng S, Sakdapipanich J, Nasongkla N. 2012. Preparation of self-solidifying polymeric depots from PLEC-PEG-PLEC triblock copolymers as an injectable drug delivery system. J Polym Res 19:9834.
20. Boongird A, Nasongkla N, Hongeng S, Sukdawong N, Sa-nguanruang W, Larbcharoensub N. 2011. Biocompatibility study of glycofurol in rat brains. Exp Bio Med (Maywood) 236(1):77-83.
21. Nasongkla N, Boongird A, Hongeng S, Manaspon C, Larbcharoensub N. 2012. Preparation and biocompatibility study of in situ forming polymer implants in rat brains. J Mater Sci Mater Med 23(2):497-505.
22. Hou H, Siegel RA. 2006. Enhanced permeation of diazepam through artificial membranes from supersaturated solutions. J Pharm Sci 95(4):896-905.
23. Löscher W, Hönack D. 1997. Intravenous carbamazepine: Comparison of different parenteral formulations in a mouse model of convulsive status epilepticus. Epilepsia 38(1):106-113.
24. Hu Y, Jiang X, Ding Y, Zhang L, Yang C, Zhang J, Chen J, Yang Y. 2003. Preparation and drug release behaviors of nimodipine-loaded poly(caprolactone)-poly(ethylene oxide)-polylactide amphiphilic copolymer nanoparticles. Biomaterials 24(13):2395-2404.
25. Dash S, Murthy PN, Nath L, Chowdhury P. 2010. Kinetic modeling on drug release from controlled drug delivery systems. Acta Pol Pharm 67(3):217-223.
26. Sano K, Yoshikawa M, Hayasaka S, Satake K, Ikegami Y, Yoshida H, Ishikawa T, Sawada S, Tanabe S. 2003. Simple non-ion-paired high-performance liquid chromatographic method for simultaneous quantitation of carboxylate and lactone forms of 14 new camptothecin derivatives. J Chromatogr B Analyt Technol Biomed Life Sci 795(1):25-34.
27. Xuan T, Zhang JA, Ahmad I. 2006. HPLC method for determination of SN-38 content and SN-38 entrapment efficiency in a novel liposome-based formulation, LE-SN38. J Pharm Biomed Anal 41(2):582-588.
28. Cerral P, Tricoli M, Lelli L, Guerra GD, Sbarbati Del Guerra R, Cascone MG, Giusti P. 1994. Block copolymers of l-lactide and poly(ethylene glycol) for biomedical applications. J Mater Sci Mater Med 5(6-7):308-313.
29. Sharifi S, Mirzadeh H, Imani M, Rong Z, Jamshidi A, Shokrgozar M, Atai M, Roohpour N. 2009. Injectable in situ forming drug delivery system based on poly(ε-caprolactone fumarate) for tamoxifen citrate delivery: Gelaion characteristics, in vitro drug release and anti-cancer evaluation. Acta Biomater 5(6):1966-1978.
30. Souza RD, Zahedi P, Allen CJ, Piquette-Miller M. 2009. Biocompatibility of injectable chitosan-phospholipid implant systems. Biomaterials 30(23-24):3818-3824.
31. Timmer MD, Shin H, Horch RA, Ambrose CG, Mikos AG. 2003. In vitro cytotoxicity of injectable and biodegradable poly(propylene fumarate)-based networks: Unreacted macromers, cross-linked networks, and degradation products. Biomacromolecules 4(4):1026-1033.
32. Kryczka T, Bero M, Kasperczyk J, Dobrzyński P, Marciniec B, Popielarz-Brzezińska M, Grieb P. 2002. In vitro release of cytotoxic nucleoside analogs from lactide-caprolactone and lactide-glycolide copolymers. Acta Biochim Pol 49(1):205-210.
33. Cheng L, Guo S, Wu W. 2009. Characterization and in vitro release of praziquantel from poly(ε-caprolactone) implants. Int J Pharm 377(1-2):112-119.
34. Wang X, Wang Y, Wei K, Zhao N, Zhang S, Chen J. 2009. Drug distribution within poly(ε-caprolactone) microspheres and in vitro release. J Mater Process Tech 209(1):348-354.
35. DesNoyer JR, McHugh AJ. 2001. Role of crystallization in the phase inversion dynamics and protein release kinetics of injectable drug delivery systems. J Control Release 70(3):285-294.
36. Ahmed F, Discher DE 2004. Self-porating polymersomes of PEG-PLA and PEG-PCL: Hydrolysis-triggered controlled release vesicles. J Control Release 96(1):37-53.